Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Relapsing encephalomyelitis following transfer of partial immunity to JHM virus

Richard A. Shubin, Mark A. Sussman, John O. Fleming and Stephen A. Stohlman

Departments of Neurology and Microbiology, The University of Southern California School of Medicine, Los Angeles, CA 90033, U.S.A.

(Received January 5, 1989; accepted in revised form September 8, 1989)

Mice infected with the JHM strain mouse hepatitis virus (JHMV) develop a fatal encephalomyelitis with evidence of demyelination. It has previously been shown that the adoptive transfer of 5 x 10^7 nylon wool adherent (NWA) spleen cells from immunized donors to lethally infected recipients clears virus from the central nervous system (CNS) and prevents demyelination. Adoptive transfer of a smaller number (1 x 10^7) of NWA spleen cells from immunized donors also protects from death but does not significantly alter virus replication in the CNS during the acute phase of the infection. Moreover, these mice develop a transient non-fatal encephalomyelitis which occurs approximately 3 weeks post-infection. This delayed encephalomyelitis is associated with a mononuclear cell infiltration into the CNS but little or no evidence of virus replication or increased viral antigen. A virus-specific delayed-type hypersensitivity (DTH) response precedes this delayed onset of disease by 24 to 48 h. Resolution of disease correlates with a selective and permanent suppression of the JHMV-specific DTH reactivity. In addition, no virus-specific DTH is detected following adoptive transfer of viral-specific DTH effectors derived from immunized donors. In contrast, these mice respond to a heterologous antigen, KLH, suggesting that the resolution of the encephalitis is accompanied by a profound suppression in viral-specific DTH response.

Key words: coronaviruses; neurovirulence; delayed-type hypersensitivity; cellular immunity.

Introduction

The JHM strain of mouse hepatitis virus (JHMV) is a murine coronavirus which causes acute encephalitis and both acute and chronic demyelination in mice and rats. JHMV infection has been studied extensively as a model of multiple sclerosis, which may be caused by a viral infection encountered early in life that triggers an autoimmune response to oligodendrocytes and/or myelin components in individuals with an appropriate genetic background. Our laboratory has been investigating the role of the
immune system in the pathogenesis of JHMV-induced disease and the ability of immune therapy to modify the course of disease. Mice and rats infected with JHMV have an acute neutralizing encephalomyelitis with neuronophagia. To understand the pathogenesis of encephalitis and demyelination following JHMV infection of the CNS, we and others have examined the roles of the humoral and cellular immune response to JHMV and related mouse hepatitis viruses (MHV). Rodents can be protected from death by administration of monoclonal antibodies specific for the three virus structural proteins, E1, E2, and the nucleocapsid protein. Wege et al., demonstrated in rats that only anti-E2 monoclonal antibodies which neutralized virus and prevented cell fusion were protective. Protection by virus-specific monoclonal antibodies in mice is associated with sparing of neurons during JHMV infection and the subsequent development of subacute demyelination.

Other studies have focused on the protective role that cellular immunity may play in JHMV pathogenesis. Using the adoptive transfer of JHMV-immune spleen cells into JHMV-challenged recipients, two distinct protective T lymphocyte populations have been identified. First, nylon wool non-adherent (NWNA) cells (Thy 1+, CD4+, Lyt-2-) will induce a delayed-type hypersensitivity (DTH) response in recipients. These cells are restricted by major histocompatibility complex (MHC) Class II (I-A) identify between donor and recipient. Protected mice show vigorous perivascular mononuclear cell responses in the CNS but viral replication is not suppressed, and surviving mice show marked demyelination in central white matter. Second, nylon wool adherent (NWA) cells (Thy 1+, CD4+, Lyt-2-) will protect mice, suppress viral replication, and prevent demyelination. The effect of these cells is dependent on MHC Class I (H-2 D) identify between donor and recipient and is blocked by administration of anti-CD8 antibody to the recipient. Protection mediated by the administration of either donor NWNA CD4+ or NWA CD4+ populations is prevented by immunosuppression of the recipients, implying that both donor T cell populations function primarily as helpors for host cells. Thus, NWNA CD4+ cells induce a DTH response, prevent a lethal encephalitis, but are unable to block viral replication and subsequent demyelination; NWA CD4+ cells induce CD8+ effecters cells which protect mice, reduce viral replication, and prevent demyelination.

In the present report we have focused on the influence of the second T helper population, CD4+ NWA cells, on JHMV-induced demyelination. Interestingly, when a reduced number of these cells are administered, sufficient to protect only partially from an ordinarily lethal JHMV challenge, many recipient surviving mice show a biphasic, relapsing disease. This finding is consistent with the observation that chronic CNS pathology often occurs when there is an equivalence or balance between the ability of a virus to replicate and the ability of immune system to clear the virus. We have also found that the onset and resolution of delayed disease is correlated with the level of anti-JHMV cellular immunity in these mice. This system provides a useful model for dissecting the regulation of immunological responses to a viral infection of the CNS with regard to clinically relevant phenomena, such as the onset and resolution of an episode of demyelination.

Results

Kinetics of the biphasic disease

The adoptive transfer of NWA, but not NWNA cells, from immunized donors to lethally infected mice mediates the clearance of JHMV. Previous results from our laboratory have indicated that the active cells in this population are CD4+ T cells that function by providing help for CD8+ cells, because treatment of the recipients with anti-Lyt-2
Table 1  The effect of transfer of nylon wool adherent spleen cells into JHMV-infected mice

| Number of cells transferred<sup>a</sup> | Live<sup>b</sup> / total | Viral titer<sup>c</sup> | Percent<sup>d</sup> with late disease | Cellular infiltrate<sup>e</sup> | JHMV antigen<sup>f</sup> |
|------------------------------------|------------------------|------------------------|----------------------------------|-----------------------------|-------------------------|
| None                               | 0/11                   | 5.3±0.4                | -                                | ++                         | ++                     |
| 5x10<sup>7</sup>                   | 8/8                    | 2.1±0.4                | 0                                | 0                          | 0                      |
| 1x10<sup>7</sup>                   | 24/28                  | 4.5±1.0                | 83%                              | +++                        | +                      |
| 5x10<sup>6</sup>                   | 1/11                   | 4.5±1.0                | 0                                | ++                        | +                      |
| 5x10<sup>5</sup>                   | 0/5                    | 6.0±1.0                | -                                | ++                        | ++                     |

<sup>a</sup>Nylon wool adherent spleen cells from immunized mice.
<sup>b</sup>At 30 days post-infection.
<sup>c</sup>Log pfu per g brain at 5 days post-infection.
<sup>d</sup>At 21 days post i.c. inoculation.
<sup>e</sup>O = absent, + = scanty (occasional positive cells). ++ = abundant (many positive cells).
<sup>f</sup>Not applicable.
<sup>g</sup>At 5 days post-infection.

(CD8<sup>+</sup>) monoclonal antibody prevents the reduction of JHMV in the CNS." Table 1 shows that adoptive transfer of 5x10<sup>7</sup> NWA cells results in the reduction of JHMV in the brain of infected mice as previously described." To determine the number of cells required for protection, 1x10<sup>7</sup> and 5x10<sup>6</sup> NWA cells were transferred. The transfer of 1x10<sup>7</sup> NWA cells also protects against lethal JHMV infection; however, this cell number does not mediate reduction of the viral titer in the CNS (Table 1). Adoptive transfer of 5x10<sup>6</sup> or fewer cells neither protected mice nor cleared virus from the CNS (Table 1). Complement-mediated antibody depletions prior to transfer of 1x10<sup>7</sup> NWA cells per recipient indicated that the phenotype of the cell responsible for protection is a CD4<sup>+</sup> T cell (data not shown), similar to our previously published report."  

Clinical course of the biphasic disease
The quantity of NWA cells transferred during infection not only determines survival and the clearance of virus from the CNS but also the clinical course of the disease (Table 1). Control mice which received JHMV and no NWA cells showed clinical evidence of acute encephalomyelitis (ruffled fur, hyperexcitibility, and myoclonus) on day 11 post-infection and died by day 14." Mice which received 5x10<sup>7</sup> NWA cells did not manifest any clinical signs of encephalomyelitis following infection." In contrast, most mice which received the intermediate number of NW cells (1x10<sup>7</sup>) developed a non-fatal encephalitis. Figure 1 outlines the incidence of clinical disease in this group. All mice appeared normal until day 11. At that time, a subgroup (5 out of 24 or 22%) developed encephalomyelitis of variable severity from which a minority (1 out of 5 or 25%) died. The remainder of this subgroup recovered clinically by day 14. On approximately day 21 post-infection (17 out of 20 or 85%) develop a second episode of encephalomyelitis of variable severity. This second phase was lethal for one out of the 17 or 5% of the mice; however, the majority (15 of 16) exhibit signs of transient encephalomyelitis which resolves by day 25 post-infection.

Viral titer and histopathology
During lethal infection under conditions noted in the Materials and methods section with JHMV, maximum viral titer in the CNS occurs at 5 day post-infection." There is abundant viral antigen demonstrated immunohistochemically as well as marked infiltration of mononuclear cells seen throughout the CNS (Table 1). Figure 2(a)
Fig. 1. Clinical course of JHMV infected recipients of $1 \times 10^7$ NWA spleen cells from immunized donors. Encephalitis and paralysis was assessed using the criteria given in the Materials and methods section. Note that the majority of mice show signs of encephalomyelitis at day 21. Mice which do not receive NWA cells become sick at day 10 and die by day 14 post infection.

shows a representative section of cerebrum exhibiting abundant viral antigen in both neurons and glia. The degree of cellular infiltration in the CNS reaches a plateau at 7 days post-infection and remains constant until death at day 14 post-infection. In contrast, the transfer of $5 \times 10^7$ NWA cells at the time of intercerebral (i.c.) inoculation dramatically reduces viral titer in the CNS$^{11}$ and results in minimal histological evidence of disease. A photomicrograph of the same region of brain as above [Fig. 2(b)] reveals an absence of viral antigen in both neurons and glia following the transfer of $5 \times 10^7$ NWA cells. By contrast, Table 1 shows that the protection mediated by adoptive transfer of $1 \times 10^7$ NWA cells only reduces viral titer 0.8 log$_{10}$ pfu/g relative to the untreated controls at day 5, although the transfer of this number of NWA cells protects mice from death. Although it results in earlier clearance of virus (Table 2), histological examination shows that there is abundant viral antigen in both neurons and glial cells and a marked infiltration into the brain parenchyma, primarily in the white matter [Fig. 2(c)], similar to the controls [Fig. 2(a)].

In the second phase of clinically apparent disease begins at day 21 post-infection and is associated with a marked cellular infiltration into both white and gray matter [Fig. 2(d)]. A corresponding increase in infectious virus or viral antigen was not observed at this time, although occasional mice had low levels of infectious virus or occasional foci of viral antigen in areas not associated with cellular infiltration or demyelination (data not shown). These findings are consistent with previous studies$^{9,12}$ showing that viral antigen is generally not present in lesions at the time of demyelination and suggesting that disease may develop in areas in which active clearance of virus occurs.

**Immune response in protected mice**

JHMV-specific antibody levels were examined to determine the role of humoral immunity in protection afforded by adoptive transfer of $1 \times 10^7$ NWA cells. The anti-JHMV IgG response$^{12}$ in both recipients and controls not given NWA cells was similar in both in kinetics and magnitude (data not shown). Similar antibody titers were obtained following the adoptive transfer of CD4$^+$ DTH inducer T cells, which also protected without altering virus replication in the CNS.$^6$

The JHMV-specific DTH response was assessed as a measure of cell-mediated immunity in mice protected by adoptive transfer of $1 \times 10^7$ NWA cells. Six days after intraperitoneal (i.p.) immunization with JHMV, mice exhibit a vigorous DTH response
Fig. 2. Viral antigen in the CNS of mice infected with JHMV (immunoperoxidase; ×300). (a) Cerebrum at 5 days post-infection. Note large amounts of viral antigen in neurons and glia. (b) Cerebrum of a recipient of 5×10⁷ NWA cells at 5 days post-infection. Note absence of antigen in either neurons or glia. (c) Cerebrum of a recipient of 1×10⁷ NWA cells at 5 days post-infection. Note large amounts of viral antigen in neurons and glia comparable to (a). (d) Spinal cord of a recipient of 1×10⁷ NWA cells at 24 days post-infection. Note the lack of correlation between the presence of mononuclear infiltrate in the white and gray matter and viral antigen in the white matter.
Table 2  Replication of JHMV in NWA cell recipients

| Day post-infection | NWA cell recipients | Untreated controls |
|--------------------|---------------------|--------------------|
| 5                  | 5.7 ± 0.5           | 6.0 ± 0.3          |
| 7                  | 2.7 ± 1.0           | 4.3 ± 0.5          |
| 10                 | 2.8 ± 1.0           | 2.8 ± 0.8          |
| 12                 | -c                 | 2.3 ± 0.5          |
| 15                 | -c                 | NA*                |
| 30                 | -c                 | NA*                |

* Log pfu per g brain tissue.  
* The adoptive transfer of $1 \times 10^7$ NWA cells from immunized donors immediately prior to infection. Untreated mice were infected but received no NWA cells.  
* Undetectable ($\leq 10^2$ pfu/g of brain).  
* NA = not applicable (untreated mice all die by day 14 post-infection).

elicited by the injection of viral antigen into the footpad. We have previously shown that NWA cells do not mediate a virus-specific DTH response; in addition, mice infected with JHMV by intracerebral inoculation and not protected by donor splenocytes do not develop a measurable DTH response prior to death (data not shown). Table 3 (experiment 1) confirms that mice immunized i.p. exhibit an excellent virus-specific DTH response. Furthermore, the adoptive transfer of unseparated spleen cells or NWNA cells from immunized donors to naive recipients also results in a virus-specific DTH response. However, as shown previously, the transfer of NWA cells to naive recipients does not result in the induction of a virus-specific DTH response (Table 3, experiment 2). Table 3 (experiment 3) shows that mice infected i.c. with JHMV and subsequently given NWA cells by adoptive transfer do not exhibit a DTH response until 18 days post-infection. This is coincident with the development of the late phase of the disease (Fig. 1). The DTH response is transient and disappears by day 24. The loss of DTH responsiveness corresponds to the resolution of the late disease by day 24.

Table 4 shows the results of two additional experiments. First, naive mice and JHMV-infected NWA cell recipients were immunized and then challenged with keyhole lympet hemocyanin (KLH). In experiment 1, we demonstrated that the DTH response to KLH was similar in both groups. To determine if the loss of DTH reactivity to JHMV was due to active JHMV-specific suppression, we performed experiment 2 in which NWNA DTH effector T cells from JHMV immunized mice were adoptively transferred into naive recipients and NWA cell recipients which had recovered from the late encephalomyelitis. All mice were challenged immediately with JHMV antigen and the DTH response measured 24 h later. The average DTH response in naive mice was $27.2 \times 10^{-2}$ mm. In contrast, an average DTH response of only $5.1 \times 10^{-2}$ mm was found in NWA cell protected mice. This suggests that the lack of a DTH response to JHMV in NWA cell protected mice is the result of viral-specific suppression, since both groups responded equally to KLH.

Discussion

JHMV infection has been extensively studied as a model of acute and chronic viral infection of the CNS. The analysis of antigenic variants isolated by selection
Table 3  Delayed-type hypersensitivity response to JHMV

| Immune status | Cells transferred | Day tested | DTH response<sup>a</sup> (x10<sup>-2</sup> mm) |
|----------------|-------------------|------------|-------------------|
| Experiment 1<sup>b</sup> | Immunized i.p. | None | 6 | 67.5 ± 21.9 |
| | | | 6 | 9.4 ± 5.2 |
| Experiment 2<sup>c</sup> | Naive | None | 1 | 9.7 ± 6.9 |
| | | Whole spleen<sup>e</sup> | 1 | 29.3 ± 5.2 |
| | | NWNA<sup>f</sup> | 1 | 40.2 ± 5.3 |
| | | NWA<sup>g</sup> | 1 | 9.9 ± 6.8 |
| Experiment 3<sup>d</sup> | JHMV infected i.c. | NWA | 10 | 9.7 ± 8.9 |
| | | | 15 | 0.0 ± 5.0 |
| | | | 18 | 62.0 ± 14.1 |
| | | | 21 | 24.2 ± 8.6 |
| | | | 24 | 7.6 ± 8.1 |
| | | | 30 | 15.3 ± 13.3 |
| | | | 45 | 6.3 ± 7.1 |
| | | | 60 | 14.5 ± 7.8 |
| | | | 75 | 9.2 ± 11.9 |
| | | | 100 | 0.5 ± 5.0 |

<sup>a</sup> Results expressed as the difference of the right footpad minus the left footpad ± one SD 24 h after the injection of JHMV Ag 20 µl into the right footpad and PBS 20 µl into the left footpad.

<sup>b</sup> Immunized (i.p.) and infected (i.c.) C57BL/6 mice were challenged at day 5 and the DTH response was measured on day 6.

<sup>c</sup> 1 x 10<sup>7</sup> spleen cells, NWNA cells or NWA cells from immunized donors were transferred to naive C57BL/6. Recipients were challenged immediately and the DTH response was measured 24 h later.

<sup>d</sup> C57BL/6 mice which received 1 x 10<sup>7</sup> NWA cells from immunized donors were infected (i.e.) with JHMV on day 0. Recipients were challenged with antigen and the DTH response measured 24 h later.

<sup>e</sup> 1 x 10<sup>7</sup> spleen cells from C57BL/6 donors immunized 6 days previously by intraperitoneal injection of 1 x 10<sup>6</sup> pfu of JHMV.

<sup>f</sup> 5 x 10<sup>7</sup> NWNA cells from C57BL/6 donors immunized 6 days previously by intraperitoneal injection with 1 x 10<sup>6</sup> pfu of JHMV.

<sup>g</sup> 5 x 10<sup>7</sup> NWA cells from C57BL/6 donors immunized 6 days previously by intraperitoneal injection of 1 x 10<sup>6</sup> pfu of JHMV.

Table 4  Delayed-type hypersensitivity response of NWA cell recipients

| Immune status | Antigen | NWNA effector cells | DTH response<sup>a</sup> (x10<sup>-2</sup> mm) |
|----------------|---------|---------------------|-------------------|
| Experiment 1<sup>*</sup> | Naive NWA cell recipient | KLH | - | 30.9 ± 12.2 |
| | | KLH | - | 36.3 ± 11.9 |
| Experiment 2<sup>+</sup> | Naive NWA cell recipient | JHMV | + | 27.2 ± 5.2 |
| | | JHMV | + | 5.1 ± 3.8 |

<sup>*</sup> Groups of naive and NWA cell recipients were immunized with KLH, challenged in the footpad 5 days later and the DTH response to KLH determined 24 h later.

<sup>+</sup> 1 x 10<sup>9</sup> NWNA cells from JHMV immune donors were transferred to groups of naive and NWA cell recipients. Mice were challenged in the left footpad with JHMV and in the right with PBS. The DTH response was measured 24 h later.
with neutralizing monoclonal antibodies have implicated the virus major envelope
glycoprotein, designated E2, as a determinant of tropism for cell types within the
CNS. However, it is also apparent that the immune competence of the host plays
a major role in determining the outcome of infection. For example, the passive transfer
of both neutralizing and non-neutralizing monoclonal antibodies specific for both the
E2 glycoprotein, which contains the neutralization determinant, and for the E1 matrix
protein, can protect mice from a lethal JHMV infection. The mechanism of protection
is not well understood. However, it has been suggested, based on histological evidence,
that these antibodies alter the apparent cell tropism for the virus within the CNS. The
role of the cellular components of the immune system in providing protection and
suppressing virus replication within the CNS has been less well studied. The transfer
of the CD4+ T cell population contained in the NWA population is also able to confer
protection from a lethal JHMV infection. However, these cells could be distinguished
from the CD4+ DTH-inducer effector T cells previously described in that they were
unable to adoptively transfer a viral-specific DTH response. Further, protection was
mediated via a suppression of virus replication within the CNS. This CD4+ NWA
population functions as a helper cell facilitating the induction of a CD8+ effector
which requires Class I histocompatibility with the donor population.

In the present study, we have confirmed that the adoptive transfer of non-DTH
inducer T cells can protect mice from a lethal JHMV infection. When high numbers
(5 x 10^6) are transferred, the recipients show no evidence of either acute or persistent
disease. Alternatively, when the number of cells transferred is reduced to 1 x 10^7,
there is only a minimal effect on virus replication within the CNS. The transfer of even
fewer CD4+ NWA cells (5 x 10^6) was unable to alter virus replication within the CNS
or to protect mice from a lethal infection. Surprisingly, recipients of 1 x 10^7 NWA cells
undergo a biphasic clinical disease wherein the second delayed phase of encephalitis
is not caused by an increase in virus replication within the CNS. In addition, the data
suggest that the second phase of disease corresponds to the development of a virus
specific DTH response. Similar to our previous findings, the development of the
DTH response does not result in the reduction of viral antigen within the CNS. The
sublethal demyelinating process in these NWA cell recipients occurs in the white
matter of both the brain and spinal cord and is accompanied by mononuclear cell
infiltrations. The clinical and histological disease in these NWA cell recipients is similar
to the description of subacute demyelinating encephalomyelitis that occurs after the
infection of neonatal rats. Although the immunological basis for the recurrent
demyelination in the rats is not known, it has been suggested that T cells specific for
antigens within the CNS may play at least a partial role in the induction of this
disease. The role of autoimmune cells in the murine model has yet to be examined;
however, it is clear from both these models that the immune system may play a
critical role in both the establishment and maintenance of JHMV-induced chronic
demyelination of the CNS.

The resolution of the clinical disease in the NWA cell recipients corresponds with
the suppression of the virus-specific DTH response. This suppression is virus-specific
because we have demonstrated that these mice are still able to respond to heterologous
antigen. These data are consistent with our previous data demonstrating that the DTH
response plays a major role in the induction of acute demyelination following JHMV
infection. The DTH response is a complex of cell-cell interactions that are initiated
by the recognition of antigen in the context of MHC Class II molecules expressed on
antigen-presenting cells by CD4+ effector cells. The breakdown of vascular permeability
and the recruitment of mononuclear cells into the site are both mediated by lympho-
kines, including gamma interferon; however, a variety of other lymphokine and
soluble products participate in the induction of this response. The suppression of the DTH response may reflect an attempt of the host to reduce the adverse effects of increased vascular permeability and the infiltration of activated monocytes. Consistent with our previous results, protection from death was not due to the suppression of viral replication in the CNS, however, in contrast to our previous data, protection was not correlated with a virus-specific DTH response. The data presented in this report have demonstrated that the adoptive transfer of partial immunity to mice lethally infected with JHMV results in protection from death and the induction of a relapse of disease that is correlated with the virus-specific DTH response.

Materials and methods

Mice. C57BL/6 male 5-week-old mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). Mice were used within 8 days of arrival. Sera obtained from representative mice were tested for JHMV antibody by enzyme-linked immunosorbent assay (ELISA) as previously described and were found to be seronegative.

Virus. JHMV was propagated in DBT cells, a continuous murine astrocytoma, as previously described. Mice were inoculated i.c. with $5 \times 10^4$ plaque forming units (pfu) of the DS strain in a volume of 0.03 ml. Animals succumb to this infection with acute encephalomyelitis with evidence of demyelination within 14 days of infection. Donor mice were immunized i.p. with $1 \times 10^6$ pfu of JHMV as previously described.

Adoptive transfer. Six days after immunization, donor spleens were removed aseptically, teased and the cells were washed twice in RPMI 1640 medium (Gibco Laboratories, Grand Island, New York). Cells were resuspended in RPMI medium supplemented with 10% fetal calf serum (FCS; Irvine Scientific, Irvine, California). Approximately $8 \times 10^6$ cells were adsorbed for 1 h onto a nylon wool column containing 2.4 g of nylon wool (Fenwall, Morton Grove, Illinois) prepared in a 35-ml syringe as previously described. The NWNA were collected by washing the column with three volume equivalents of RPMI medium containing 10% FCS. NWA cells were dislodged by allowing the column to run dry and then refilling it with ice cold Earle's balanced salt solution (Gibco Laboratories). The cells were expelled from the column using the syringe plunger. NWA cells were washed twice and resuspended in RPMI medium at the appropriate concentrations. Cells were administered by i.v. injection immediately prior to i.c. injection with JHMV.

Virus titration. The virus titer in brain was determined by limiting dilution of clarified homogenates on monolayers of L-2 cells as previously described. Titer was calculated from duplicate assays derived from three–four mice per group and the results expressed as the mean titer per g of brain.

Clinical assessment. Mice were examined for signs of encephalitis and paralysis at least every other day for the first month and at least three times per week for all subsequent points. Clinical changes were scored using the system described by Fleming et al. Encephalitis was scored as present if mice were either: easily excitable, slightly or severely hunched, had ruffled fur or were lethargic. Paralysis was rated present if mice were ataxic, or exhibited hind limb paresis or paralysis.

Histology. Brains and spinal cords were fixed by immersion in Clarke's fixative for 3 h prior to paraffin embedding. Sections (7 μm) were stained with Erlich's hematoxylin and eosin or luxol fast blue, dehydrated and mounted in permount prior to light microscopy. Adjacent tissue sections for immunohistochemistry were stained by an avidin-biotin immunoperoxidase procedure (Vectastain, Vector Laboratories, Burlingame, California) using monoclonal antibody J.3.3, specific for the JHMV nucleocapsid protein, as the primary antibody. Horizontal sections through the basal ganglia and hippocampus and longitudinal sections of spinal cord were examined. Perivascular cuffing, parenchymal infiltrate in gray and white matter, the quantity of viral antigen in gray and white matter, and the distribution of viral antigen in neurons and glia were scored as follows: n, normal; +, slight; ++, moderate; ++++, severe.
Delayed type hypersensitivity. Footpad swelling was used as a measure of the DTH response as previously described. A lysate of infected DBT cells sonicated in phosphate buffered saline (PBS), pH 7.2, prepared as previously described, was used as antigen. Mice were immunized with 150 μg of KLH (Calbiochem, La Jolla, California) by i.p. injection. Five days later mice were injected with 20 μl containing 150 μg of KLH in PBS in the right footpad. Injection of 20 μl of PBS in the left footpad served as control. The dorso-ventral thickness was measured 24 h later using a Mitutoyo micrometer (Tokyo, Japan). Data are presented as the difference of the right foot minus the left foot plus or minus one SEM.

Anti-virus antibody. Blood was obtained from anesthetized mice by cardiac puncture. Anti-JHMV antibodies in serum samples from individual mice were measured by ELISA. The concentration of antibody in sera was determined by probit analyses in comparison with IgG standards obtained from mice hyperimmunized with JHMV.

We are grateful to Cindy Fabricius-Segal and Ligaya Pen for excellent technical assistance and to Carol Flores for excellent editorial assistance.

References

1. Wege H, Siddell S, ter Meulen V. The biology and pathogenesis of coronaviruses. Curr Top Microbiol Immunol 1982; 99: 165–200.
2. Waksman BH, Reingold SC. Viral etiology of multiple sclerosis: where does the truth lie. Trends Neurosci 1986; 9: 388–91.
3. Fleming JO, Shubin RA, Sussman MA, Casteel N, Stohlman SA. Monoclonal antibodies to the matrix (E1) glycoprotein of mouse hepatitis virus protect mice from encephalitis. Virology 1989; 168: 162–7.
4. Buchmeier MJ, Lewicki HA, Talbot PK, Knobler RL. Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology 1984; 132: 261–70.
5. Wege H, Dorries R, Wege H. Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E2). J Gen Virol 1984; 65: 1931–42.
6. Nakamura K, Yamanouchi K, Fujimura K. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J Virol 1986; 59: 168–71.
7. Zecomte J, Cainelli-Gebara V, Mercier G et al. Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Arch Virology 1987; 97: 123–30.
8. Stohlman SA, Matsushima G, Casteel N, Weiner LP. In vivo effects of coronavirus-specific T cell clones. DTH inducer cells prevent a lethal infection, but do not inhibit virus replication. J Immunol 1986; 136: 3052–6.
9. Stohlman SA, Sussman MA, Matsushima GK, Shubin RA, Erlich SS. Delayed-type hypersensitivity response in the central nervous system during JHM virus infection requires viral specificity for protection. J Neuroimmunol 1988; 19: 255–68.
10. Erlich SS, Matsushima GK, Stohlman SA. Studies on the mechanism of protection from acute encephalomyelitis by delayed-type hypersensitivity T cell clones. J Neurol Sci 1990; 90: 203–16.
11. Sussman MA, Shubin RA, Kyuwa S, Stohlman S. T cell mediated clearance of mouse hepatitis virus, strain JHM, from the central nervous system. J Virol 1989; 63: 3051–6.
12. Fleming JO, Trousdale MD, El-Zaatari FAK, Stohlman SA, Weiner LP. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J Virol 1986; 58: 869–75.
13. Talbot PJ, Buchmeier MJ. Specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J Virol 1986; 59: 463–71.
14. Nagashima K, Wege W, Meyerman R, ter Meulen V. Coronavirus induced subacute demyelinating encephalomyelitis in rats: a morphological analysis. Acta neuropathol (Berl) 1978; 44: 63–70.
15. Watanabe R, Wege H, ter Meulen V. Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature 1983; 305: 150–3.
16. Issekutz TB, Stoltz JM, Meide P. Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-γ. J Immunol 1983; 140: 2989–93.
17. Geczy CL. The role of lymphokines in delayed-type hypersensitivity reactions. Springer Semin Immunopathol 1984; 7: 321–46.
18. Fleming JO, Stohlman SA, Harmon RC, Lai MMC, Frelinger JA, Weiner LP. Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus. Virology 1983; 131: 296–307.
19. Woodward JG, Matsushima GK, Frelinger JA, Stohlman SA. Production and characterization of T cell clones specific for mouse hepatitis virus, strain JHM: in vivo and in vitro analyses. J Immunol 1984; 133: 1016–21.